Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies

Journal of Clinical Psychiatry

Volumn 73, Issue 8, 2012, Pages

  Cerimele, Joseph M ^a,b   Durango, Alejandra ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

AGGRESSION; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; COGNITIVE DEFECT; DELUSION; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPHORIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPONATREMIA; INSOMNIA; IRRITABILITY; MANIA; MOOD; MUSCLE STIFFNESS; NAUSEA; NAUSEA AND VOMITING; PARANOIA; PERSECUTORY DELUSION; POLYDIPSIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TOBACCO DEPENDENCE; VOMITING; XEROSTOMIA;

EID: 84865758663     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11r07410     Document Type: Article

References (54)

1. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10(12):1691-1715. doi:10.1080/1462080243569 PubMed
2. Schroeder SA. A 51-year-old woman with bipolar disorder who wants to quit smoking. JAMA. 2009;301(5):522-531. doi:10.101/jama.208.982 PubMed
3. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
4. Druss BG, Bornemann TH. Improving health and health care for persons with serious mental illness: the window for US federal policy change. JAMA. 2010;303(19):1972-1973.
5. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry. 2007;68(suppl 4):40-44. PubMed
6. Fiore M, Jaen CR, Baker TB. Tobacco Use and Dependence: 2008 Update: Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services; 2008.
7. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55. doi:10.101/jama.296.1.47 PubMed
8. Prochaska JJ. Smoking and mental illness - breaking the link. N Engl J Med. 2011;365(3):196-198. doi:10.1056/NEJMp105248 PubMed
9. Montoya ID, Vocci F. Medications development for the treatment of nicotine dependence in individuals with schizophrenia. J Dual Diagn. 2007;3(3-4):113-150. doi:10.130/J374v03n03-09 PubMed
10. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3(4):397-403. doi:10.1080/146201073920 PubMed
11. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004;65(3):307-311, quiz 452-453. doi:10.408/JCP.v65n0304 PubMed
12. Gelenberg AJ, de Leon J, Evins AE, et al. Smoking cessation in patients with psychiatric disorders. J Clin Psychiatry. 2007;68(9):1404-1410. doi:10.408/JCP.v68n0912 PubMed
13. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008;359(19):2018-2024. doi:10.1056/NEJMct080146 PubMed
14. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63. doi:10.101/jama.296.1.56 PubMed
15. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571-1577. doi:10.101/archinte. 16.15.1571 PubMed
16. Tonstad S, Tønnesen P, Hajek P, et al; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71. doi:10.101/jama.296.1.64 PubMed
17. US Food and Drug Administration. Drug Safety Newsletter. 2009;2(1):1-4.
18. Laine P, Marttila J, Lindeman S. Hallucinations in the context of varenicline withdrawal. Am J Psychiatry. 2009;166(5):619-620. doi:10.176/api.ajp.208.08091370 PubMed
19. May AC, Rose D. Varenicline withdrawal-induced delirium with psychosis. Am J Psychiatry. 2010;167(6):720-721. doi:10.176/api.ajp.2010.0908194 PubMed
20. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164(8):1269-1270. doi:10.176/api.ajp. 207.07010173 PubMed
21. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry. 2008;165(6):774-775. doi:10.176/api.ajp.208. 071735 PubMed
22. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13(6):511-514. PubMed
23. DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy. 2009;29(7): 852-857. doi:10.1592/phco.29.7.852 PubMed
24. Cinemre B, Akdag ST, Metin O, et al. Varenicline-induced psychosis. CNS Spectr. 2010;15(7):470-472. PubMed
25. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011; (2):CD006103
26. Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf. 2011;34(9):763-772. doi:10.2165/159450-0-0 PubMed
27. Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS ONE. 2011;6(11):e27016. doi:10.1371/journal.pone.027016 PubMed
28. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154 PubMed
29. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):1269. doi:10.176/api.ajp.207.07020326 PubMed
30. Fatemi SH. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res. 2008;103(1-3):328-329. doi:10.1016/j.schres.208. 05.02 PubMed
31. Liu ME, Tsai SJ, Yang ST. Varenicline-induced mixed mood and psychotic episode in a patient with schizoaffective disorder. CNS Spectr. 2009;14(7):346. PubMed
32. Anghelescu I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci. 2009;21(1):102-103. doi:10.176/api.neuropsych.21.1.102 PubMed
33. Ismail Z, Syms J, Blumberger D, et al. Varenicline induced polydipsia and hyponatremia in a patient with schizophrenia. Schizophr Res. 2010;119(1-3):268. doi:10.1016/j.schres.2010.01.027 PubMed
34. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008;69(6):1016. doi:10.408/JCP.v69n0620a PubMed
35. Campbell AR, Anderson KD. Mental health stability in veterans with posttraumatic stress disorder receiving varenicline. Am J Health Syst Pharm. 2010;67(21):1832-1837. doi:10.2146/ajhp10196 PubMed
36. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-154. doi:10.1/j.1360-043.207.02083.x PubMed
37. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110(1-3):149-155. doi:10.1016/j.schres.209.02.01 PubMed
38. Waldo MC, Woodward L, Adler LE. Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study. Psychiatry Res. 2010;175(1-2):179-180. doi:10.1016/j.psychres.209.01.025 PubMed
39. McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38(4):394-402. doi:10.1016/j.jsat.2010.03.07 PubMed
40. Smith RC, Zhubi A, Maloku E, et al. Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers. Schizophr Res. 2010;119(1-3):269-270. doi:10.1016/j.schres.2010.02.1064 PubMed
41. Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011;129(1):94-95. doi:10.1016/j.schres.201.02.03 PubMed
42. Dutra SJ, Stoeckel LE, Carlini SV, et al. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl). 2011;219(1):25-34. PubMed
43. Liu ME, Tsai SJ, Jeang SY, et al. Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Psychiatry Res. 2011;190(1):79-84. doi:10.1016/j.psychres.201.04. 018 PubMed
44. Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68(12):1195-1206. PubMed
45. Nino-Gomez J, Carlini S, Nemani K, et al. Safety and efficacy of varenicline in schizophrenia: preliminary data from 12-week trial. Abstract presented at the 16th Annual Meeting of the Society for Research on Nicotine and Tobacco; Feb 24-Feb 27, 2010; Baltimore, MD.
46. Shim JC, Jung DU, Jung SS, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37(3):660-668. doi:10.1038/np.201.238 PubMed
47. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805. doi:10.136/bmj.b3805 PubMed
48. Purvis TL, Nelson LA, Mambourg SE. Varenicline use in patients with mental illness: an update of the evidence. Expert Opin Drug Saf. 2010;9(3):471-482. doi:10.1517/14740310365713 PubMed
49. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163(11):1934-1942. doi:10.176/api.ajp.163.1.1934 PubMed
50. Culhane MA, Schoenfeld DA, Barr RS, et al. Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry. 2008;69(11):1743-1750. doi:10.408/JCP.v69n109 PubMed
51. Moore TJ, Glenmullen J, Furberg CD. Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother. 2010;44(9):1389-1394. doi:10.1345/aph.1P172 PubMed
52. Safety and tolerability of varenicline in schizophrenia (SATOVA). Clinica Trials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00702793?term= varenicline+AND+schizophrenia&rank=10 Updated September 23rd, 2010. Accessed August 31st, 2011.
53. Varenicline and smoking cessation in schizophrenia (VSCS). Clinical Trials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT0111114 9?term=varenicline+AND+schizophrenia&rank=2 Updated August 5th, 2011. Accessed August 31st, 2011.
54. A study of varenicline for prevention of relapse to smoking in patients with schizophrenia or bipolar disorder (SCRP). Clinical Trials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00621777?term= varenicline+AND+schizophrenia&rank=6 Updated May 23rd, 2011. Accessed August 31st, 2011.